复发性/难治性多发性骨髓瘤-话题@MedSci

#复发性/难治性多发性骨髓瘤#

12篇内容 | 699人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1670493, encodeId=56df16e0493e2, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=735741, objectId=dd07e3574140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd07e3574140, replyNumber=0, likeNumber=43, createdTime=2023-02-03, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd07e3574140, moduleTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd07e3574140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670492, encodeId=cd3d16e04927d, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, objectType=article, longId=215591, objectId=5479215591c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5479215591c2, replyNumber=0, likeNumber=38, createdTime=2022-04-18, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5479215591c2, moduleTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5479215591c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670491, encodeId=7b4216e049138, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=204420, objectId=fbc5204420da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbc5204420da, replyNumber=0, likeNumber=38, createdTime=2020-12-13, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbc5204420da, moduleTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbc5204420da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670490, encodeId=79b216e049064, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, objectType=article, longId=192943, objectId=28a119294391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a119294391, replyNumber=0, likeNumber=30, createdTime=2021-02-07, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a119294391, moduleTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a119294391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670489, encodeId=586a16e04893e, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=174848, objectId=d8fa1e484829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8fa1e484829, replyNumber=0, likeNumber=37, createdTime=2020-02-09, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8fa1e484829, moduleTitle=Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8fa1e484829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670488, encodeId=a95d16e048894, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：伊沙妥昔单抗联合泊马度胺/地塞米松可安全有效的治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=162664, objectId=aad916266487, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aad916266487, replyNumber=0, likeNumber=47, createdTime=2019-07-19, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad916266487, moduleTitle=Blood：伊沙妥昔单抗联合泊马度胺/地塞米松可安全有效的治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad916266487)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670487, encodeId=f80316e04876f, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, objectType=article, longId=154529, objectId=b94515452947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94515452947, replyNumber=0, likeNumber=37, createdTime=2019-03-20, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94515452947, moduleTitle=Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94515452947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670485, encodeId=135716e04859d, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期, objectType=article, longId=139819, objectId=01201398198e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01201398198e, replyNumber=0, likeNumber=32, createdTime=2018-08-27, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01201398198e, moduleTitle=Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01201398198e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670486, encodeId=d6a816e0486d1, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=151955, objectId=4deb1519558a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4deb1519558a, replyNumber=0, likeNumber=43, createdTime=2019-10-03, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4deb1519558a, moduleTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4deb1519558a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670484, encodeId=558016e048409, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：Venetoclax靶向治疗复发性/难治性多发性骨髓瘤的效果。, objectType=article, longId=116042, objectId=be9211604209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be9211604209, replyNumber=0, likeNumber=31, createdTime=2017-12-17, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be9211604209, moduleTitle=Blood：Venetoclax靶向治疗复发性/难治性多发性骨髓瘤的效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be9211604209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670483, encodeId=ee3616e0483b0, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=Blood：Venetoclax联合硼替佐米和地塞米松对复发性/难治性多发性骨髓瘤的潜在疗效和安全性。, objectType=article, longId=111236, objectId=af39111236d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af39111236d6, replyNumber=0, likeNumber=29, createdTime=2018-04-30, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af39111236d6, moduleTitle=Blood：Venetoclax联合硼替佐米和地塞米松对复发性/难治性多发性骨髓瘤的潜在疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af39111236d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1670482, encodeId=63c916e04827d, content=<a href='/topic/show?id=b6d642519a6' target=_blank style='color:#2F92EE;'>#复发性/难治性多发性骨髓瘤#</a>, objectTitle=复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法, objectType=article, longId=55116, objectId=9ff455116d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ff455116d1, replyNumber=0, likeNumber=35, createdTime=2015-12-16, rootId=0, userName=zhangj7117, userId=55e026702513, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ff455116d1, moduleTitle=复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ff455116d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性/难治性多发性骨髓瘤

2020-05-29

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤

2023-02-03

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！

2022-04-18

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性

2020-12-13

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比

2021-02-07

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：皮下注射达雷木单抗治疗复发性/难治性多发性骨髓瘤

2020-02-09

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：伊沙妥昔单抗联合泊马度胺/地塞米松可安全有效的治疗复发性/难治性多发性骨髓瘤

2019-07-19

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：卡非佐米相比硼替佐米可延长复发性/难治性多发性骨髓瘤患者的无进展存活期和总体存活期，且不受基础肾功能影响

2019-03-20

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Lancet oncol：卡非佐米，每周一次，比每周两次，可显著延长复发性/难治性多发性骨髓瘤患者的无进展存活期

2018-08-27

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性

2019-10-03

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：Venetoclax靶向治疗复发性/难治性多发性骨髓瘤的效果。

2017-12-17

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

Blood：Venetoclax联合硼替佐米和地塞米松对复发性/难治性多发性骨髓瘤的潜在疗效和安全性。

2018-04-30

zhangj7117 (审核中...)

前往app查看评论内容

#复发性/难治性多发性骨髓瘤#

复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法

2015-12-16

科室
- - 订阅+
  - 更多科室
工具
服务